Matthew Klein
Directeur Général chez PTC THERAPEUTICS, INC.
Fortune : 2 M $ au 31/05/2024
Profil
Matthew B.
Klein is currently the President, Chief Executive Officer & Director at PTC Therapeutics, Inc. He is also an Independent Director at Clearpoint Neuro, Inc. Additionally, he holds positions as a Director at PTC Therapeutics International Ltd.
and as a Clinical Associate Professor at Stanford University.
Previously, he served as the Chairman-Restorative Burn Surgery at the University of Washington.
He was also a Director at BioElectron Technology Corp.
from 2019 to 2020 and held the position of Chief Medical Officer & Senior Vice President at Edison Pharmaceuticals, Inc. Dr. Klein obtained his undergraduate degree from the University of Pennsylvania, his doctorate from Yale University, and his graduate degree from UW School of Public Health.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PTC THERAPEUTICS, INC.
0,07% | 22/04/2024 | 52 475 ( 0,07% ) | 2 M $ | 31/05/2024 |
CLEARPOINT NEURO, INC.
0,11% | 16/05/2024 | 29 425 ( 0,11% ) | 159 778 $ | 31/05/2024 |
Postes actifs de Matthew Klein
| Sociétés | Poste | Début |
|---|---|---|
| CLEARPOINT NEURO, INC. | Directeur/Membre du Conseil | 16/04/2020 |
| PTC THERAPEUTICS, INC. | Directeur Général | 22/03/2023 |
| Stanford University | Corporate Officer/Principal | - |
| PTC Therapeutics International Ltd. | Directeur/Membre du Conseil | - |
Anciens postes connus de Matthew Klein
| Sociétés | Poste | Fin |
|---|---|---|
BioElectron Technology Corp.
 BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Directeur Général | 01/01/2019 |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services University of Washington functions as a College/University. The company is headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Edison Pharmaceuticals, Inc.
 Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Directeur Technique/Scientifique/R&D | - |
Formation de Matthew Klein
| Yale University | Doctorate Degree |
| University of Pennsylvania | Undergraduate Degree |
| UW School of Public Health | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CLEARPOINT NEURO, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Edison Pharmaceuticals, Inc.
Edison Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Edison Pharmaceuticals, Inc. developed drugs to treat mitochondrial diseases. It offers EPI-743 and EPI-A0001, an orally absorbed small molecules. The company was founded by Guy Miller in 2005 and was headquartered in Mountain View, CA. | Health Technology |
BioElectron Technology Corp.
BioElectron Technology Corp. Miscellaneous Commercial ServicesCommercial Services BioElectron Technology Corp. is a clinical-stage biotechnology company, which engages in the research and development of therapeutics for inherited mitochondrial disease. The company was founded in 2005 and is headquartered in Mountain View, CA. | Commercial Services |
| PTC Therapeutics International Ltd. |
